PACIFIC BIOSCIENCES OF CALIFORNIA, INC.PACBEarnings & Financial Report
Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.
PACB Q3 2025 Key Financial Metrics
Revenue
$38.4M
Gross Profit
$15.9M
Operating Profit
$-38.9M
Net Profit
$-38.0M
Gross Margin
41.4%
Operating Margin
-101.1%
Net Margin
-98.9%
YoY Growth
-3.8%
EPS
$-0.13
Financial Flow
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Q3 2025 Financial Summary
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported revenue of $38.4M for Q3 2025, with a net profit of $-38.0M (-98.9% margin). Cost of goods sold was $22.5M, operating expenses totaled $54.8M.
Key Financial Metrics
| Total Revenue | $38.4M |
|---|---|
| Net Profit | $-38.0M |
| Gross Margin | 41.4% |
| Operating Margin | -101.1% |
| Report Period | Q3 2025 |
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Annual Revenue by Year
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. annual revenue history includes year-by-year totals (for example, 2024 revenue was $154.0M).
| Year | Annual Revenue |
|---|---|
| 2024 | $154.0M |
| 2022 | $128.3M |
Income Statement
| Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $55.7M | $38.8M | $36.0M | $40.0M | $39.2M | $37.2M | $39.8M | $38.4M |
| YoY Growth | 72.4% | -0.2% | -24.3% | -28.2% | N/A | -4.3% | 10.4% | -3.8% |
Balance Sheet
| Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.90B | $1.67B | $1.51B | $1.45B | $1.26B | $860.8M | $825.5M | $803.2M |
| Liabilities | $1.13B | $1.02B | $1.02B | $996.9M | $753.9M | $769.2M | $764.0M | $767.1M |
| Equity | $763.7M | $649.0M | $492.7M | $453.1M | $506.6M | $91.6M | $61.5M | $36.1M |
Cash Flow
| Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-65.2M | $-75.7M | $-54.3M | $-45.5M | $-30.6M | $-44.1M | $-29.4M | $-18.7M |
More Companies
CRSP
CRISPR Therapeutics AG
Revenue
$864.0K
Net Profit
$-130.6M
GRAL
GRAIL, Inc.
Revenue
$36.2M
Net Profit
$-89.0M
RCUS
Arcus Biosciences, Inc.
Revenue
$6.0M
Net Profit
$-135.0M
TXG
10x Genomics, Inc.
Revenue
$166.0M
Net Profit
$-16.3M
DFTX
Mind Medicine (MindMed) Inc.
Revenue
$906.0K
Net Profit
$-23.9M
ASMB
ASSEMBLY BIOSCIENCES, INC.
Revenue
$10.8M
Net Profit
$-9.2M
DTIL
PRECISION BIOSCIENCES INC
Revenue
$13.0K
Net Profit
$-21.8M